---
title: "Key facts: Hims & Hers Health shares drop 14.1%; FDA restricts weight-loss pill"
description: "Hims & Hers Health shares fell 14.1% to $19.76 after the FDA restricted access to its $49 weight-loss pill and referred the company to the DOJ for possible violations.1The FDA warned Hims & Hers Healt"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275210139.md"
published_at: "2026-02-07T20:03:01.000Z"
---

# Key facts: Hims & Hers Health shares drop 14.1%; FDA restricts weight-loss pill

> Hims & Hers Health shares fell 14.1% to $19.76 after the FDA restricted access to its $49 weight-loss pill and referred the company to the DOJ for possible violations.1The FDA warned Hims & Hers Health against claiming unapproved products as generics of approved drugs, stating it will use all enforcement tools to address false claims.2

-   Hims & Hers Health shares fell 14.1% to $19.76 after the FDA restricted access to its $49 weight-loss pill and referred the company to the DOJ for possible violations.1
-   The FDA warned Hims & Hers Health against claiming unapproved products as generics of approved drugs, stating it will use all enforcement tools to address false claims.2

### Related Stocks

- [HIMS.US - Hims & Hers Health](https://longbridge.com/en/quote/HIMS.US.md)
- [HIMY.US - Defiance Leveraged Long +Income HIMS ETF](https://longbridge.com/en/quote/HIMY.US.md)
- [HIMZ.US - Defiance Daily Target 2X Long HIMS ETF](https://longbridge.com/en/quote/HIMZ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 期权热点｜上周五 HIMS 涨 3%，部分看涨期权飙升 250% | 美东时间 02 月 13 日，HIMS 期权总成交 167327 张，看涨期权占比 68%，看跌期权占比 31%。 | [Link](https://longbridge.com/en/news/276030158.md) |
| 分析 - 美国可能会对 Hims 采取行动，包括在短暂推出 Wegovy 仿制品后进行罚款 | 特朗普政府可能会对 Hims 采取法律行动，因其试图销售诺和诺德公司的 Wegovy 减肥药的复合版本。在 FDA 警告潜在违规后，Hims 已撤回相关计划。FDA 已将此案移交给司法部，司法部可能会处以罚款或寻求禁令。Hims 产品的合法 | [Link](https://longbridge.com/en/news/276042978.md) |
| 斥资 185 亿美元牵手石药集团后，阿斯利康每股收益预增双位数 | 阿斯利康预计 2026 年每股收益将实现两位数增长，肿瘤药物销售强劲有望抵消糖尿病药物专利到期影响。公司近期以高达 185 亿美元引入石药集团长效肽技术，加速布局 GLP-1 减肥药市场。尽管面临美国药价政策调整，公司通过协议获得关税豁免。 | [Link](https://longbridge.com/en/news/275425282.md) |
| 诺和诺德暴跌 8%，新减肥药片刚上市就遭” 山寨”，远程医疗公司 Hims 推出 49 美元仿制药 | 远程医疗公司 Hims 推出仿制版，定价 99 美元/月，远低于品牌药 149 美元。诺和诺德指责其” 非法复配” 并威胁起诉，声称仿制品缺乏专有保护技术无法有效吸收。Hims 辩称采用不同配方。受此影响，诺和诺德股价暴跌超 8%。 | [Link](https://longbridge.com/en/news/275044222.md) |
| 由于法律责任增加，Hims & Hers 股价再次下跌 10% | Hims & Hers Health (HIMS) 的股票因与其复合型 GLP-1 减肥药相关的监管问题再次下跌 10%。FDA 和 HHS 对安全性和营销实践表示担忧，导致诺和诺德公司因专利侵权提起诉讼。这场法律斗争可能会给 Hims 带 | [Link](https://longbridge.com/en/news/275653486.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.